First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)

Maria Alsina, Valentina Boni, Aurelia de Vries Schultink, Victor Moreno, Kees Bol, Martine Westendorp, L. Andres Sirulnik, Josep Tabernero, and Emiliano Calvo. Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.